Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024.

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.